FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2020787068> ?p ?o ?g. }

• W2020787068 endingPage "90" @default.
• W2020787068 startingPage "78" @default.
• W2020787068 abstract "Emerging preclinical and clinical evidence suggests that pregnenolone may be a promising novel therapeutic candidate in schizophrenia. Pregnenolone is a neurosteroid with pleiotropic actions in rodents that include the enhancement of learning and memory, neuritic outgrowth, and myelination. Further, pregnenolone administration results in elevations in downstream neurosteroids such as allopregnanolone, a molecule with neuroprotective effects that also increases neurogenesis, decreases apoptosis and inflammation, modulates the hypothalamic-pituitary-adrenal axis, and markedly increases GABA(A) receptor responses. In addition, pregnenolone administration elevates pregnenolone sulfate, a neurosteroid that positively modulates NMDA receptors. There are thus multiple mechanistic possibilities for pregnenolone as a potential therapeutic agent in schizophrenia, including the amelioration of NMDA receptor hypofunction (via metabolism to pregnenolone sulfate) and the mitigation of GABA dysregulation (via metabolism to allopregnanolone). Additional evidence consistent with a therapeutic role for pregnenolone in schizophrenia includes neurosteroid changes following administration of certain antipsychotics in rodent models. For example, clozapine elevates pregnenolone levels in rat hippocampus, and these increases may potentially contribute to its superior antipsychotic efficacy [Marx et al. (2006a) Pharmacol Biochem Behav 84:598-608]. Further, pregnenolone levels appear to be altered in postmortem brain tissue from patients with schizophrenia compared to control subjects [Marx et al. (2006c) Neuropsychopharmacology 31:1249-1263], suggesting that neurosteroid changes may play a role in the neurobiology of this disorder and/or its treatment. Although clinical trial data utilizing pregnenolone as a therapeutic agent in schizophrenia are currently limited, initial findings are encouraging. Treatment with adjunctive pregnenolone significantly decreased negative symptoms in patients with schizophrenia or schizoaffective disorder in a pilot proof-of-concept randomized controlled trial, and elevations in pregnenolone and allopregnanolone post-treatment with this intervention were correlated with cognitive improvements [Marx et al. (2009) Neuropsychopharmacology 34:1885-1903]. Another pilot randomized controlled trial recently presented at a scientific meeting demonstrated significant improvements in negative symptoms, verbal memory, and attention following treatment with adjunctive pregnenolone, in addition to enduring effects in a small subset of patients receiving pregnenolone longer-term [Savitz (2010) Society of Biological Psychiatry Annual Meeting New Orleans, LA]. A third pilot clinical trial reported significantly decreased positive symptoms and extrapyramidal side effects following adjunctive pregnenolone, in addition to increased attention and working memory performance [Ritsner et al. (2010) J Clin Psychiatry 71:1351-1362]. Future efforts in larger cohorts will be required to investigate pregnenolone as a possible therapeutic candidate in schizophrenia, but early efforts are promising and merit further investigation. This article is part of a Special Issue entitled: Neuroactive Steroids: Focus on Human Brain." @default.
• W2020787068 created "2016-06-24" @default.
• W2020787068 creator A5000335557 @default.
• W2020787068 creator A5018733912 @default.
• W2020787068 creator A5031075094 @default.
• W2020787068 creator A5039806245 @default.
• W2020787068 creator A5056883138 @default.
• W2020787068 creator A5062408951 @default.
• W2020787068 creator A5070608077 @default.
• W2020787068 creator A5075093461 @default.
• W2020787068 date "2011-09-01" @default.
• W2020787068 modified "2023-09-26" @default.
• W2020787068 title "Pregnenolone as a novel therapeutic candidate in schizophrenia: emerging preclinical and clinical evidence" @default.
• W2020787068 cites W1507804974 @default.
• W2020787068 cites W1554791269 @default.
• W2020787068 cites W1574849955 @default.
• W2020787068 cites W1588928891 @default.
• W2020787068 cites W1963791473 @default.
• W2020787068 cites W1967407038 @default.
• W2020787068 cites W1968700646 @default.
• W2020787068 cites W1968763887 @default.
• W2020787068 cites W1971883657 @default.
• W2020787068 cites W1973000601 @default.
• W2020787068 cites W1973059327 @default.
• W2020787068 cites W1975165097 @default.
• W2020787068 cites W1975572620 @default.
• W2020787068 cites W1976834249 @default.
• W2020787068 cites W1978748886 @default.
• W2020787068 cites W1979793519 @default.
• W2020787068 cites W1984256085 @default.
• W2020787068 cites W1987034948 @default.
• W2020787068 cites W1988293581 @default.
• W2020787068 cites W1991639159 @default.
• W2020787068 cites W1992500239 @default.
• W2020787068 cites W1993797446 @default.
• W2020787068 cites W2000712333 @default.
• W2020787068 cites W2000945972 @default.
• W2020787068 cites W2001728969 @default.
• W2020787068 cites W2001984010 @default.
• W2020787068 cites W2002947389 @default.
• W2020787068 cites W2003061257 @default.
• W2020787068 cites W2003712515 @default.
• W2020787068 cites W2005569004 @default.
• W2020787068 cites W2008639041 @default.
• W2020787068 cites W2009488399 @default.
• W2020787068 cites W2009806490 @default.
• W2020787068 cites W2010359396 @default.
• W2020787068 cites W2010987335 @default.
• W2020787068 cites W2011852864 @default.
• W2020787068 cites W2012229851 @default.
• W2020787068 cites W2013074165 @default.
• W2020787068 cites W2014357483 @default.
• W2020787068 cites W2014668639 @default.
• W2020787068 cites W2016829862 @default.
• W2020787068 cites W2016839788 @default.
• W2020787068 cites W2018769555 @default.
• W2020787068 cites W2019201578 @default.
• W2020787068 cites W2019841343 @default.
• W2020787068 cites W2020833122 @default.
• W2020787068 cites W2020847388 @default.
• W2020787068 cites W2022531328 @default.
• W2020787068 cites W2022732642 @default.
• W2020787068 cites W2023786216 @default.
• W2020787068 cites W2028466691 @default.
• W2020787068 cites W2028659881 @default.
• W2020787068 cites W2028724208 @default.
• W2020787068 cites W2028884770 @default.
• W2020787068 cites W2030945444 @default.
• W2020787068 cites W2032359153 @default.
• W2020787068 cites W2032914550 @default.
• W2020787068 cites W2034405963 @default.
• W2020787068 cites W2035244476 @default.
• W2020787068 cites W2037486805 @default.
• W2020787068 cites W2039152385 @default.
• W2020787068 cites W2039448408 @default.
• W2020787068 cites W2040397135 @default.
• W2020787068 cites W2042429529 @default.
• W2020787068 cites W2045840959 @default.
• W2020787068 cites W2047650602 @default.
• W2020787068 cites W2048397554 @default.
• W2020787068 cites W2049973822 @default.
• W2020787068 cites W2050171333 @default.
• W2020787068 cites W2051012156 @default.
• W2020787068 cites W2051614606 @default.
• W2020787068 cites W2051707916 @default.
• W2020787068 cites W2052480734 @default.
• W2020787068 cites W2053374937 @default.
• W2020787068 cites W2055112994 @default.
• W2020787068 cites W2055449376 @default.
• W2020787068 cites W2056372896 @default.
• W2020787068 cites W2058404259 @default.
• W2020787068 cites W2065518048 @default.
• W2020787068 cites W2066385861 @default.
• W2020787068 cites W2067083885 @default.
• W2020787068 cites W2068397482 @default.
• W2020787068 cites W2070510853 @default.
• W2020787068 cites W2071090720 @default.
• W2020787068 cites W2071285357 @default.

• next